- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06542874
En forskningsundersøgelse, der sammenligner, hvor godt forskellige doser af medicinen NNC0487-0111 sænker blodsukkeret hos mennesker med type 2-diabetes
Sikkerhed og effektivitet af en gang ugentlig subkutan og en gang daglig oral NNC0487-0111 hos deltagere med type 2-diabetes - en dosisbestemmelsesundersøgelse
The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.
Studieoversigt
Status
Betingelser
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Kyustendil, Bulgarien, 2500
- Individual Practice For Specialized Outpatient Medical Care Doctor Miglena Rizova Ltd.
-
Kyustendil, Bulgarien, 2500
- IPSOMC Dr. Miglena Rizova Ltd.
-
Plovdiv, Bulgarien, 4002
- DCC Sveti Georgi EOOD
-
Plovdiv, Bulgarien, 4001
- UMHAT "Kaspela", Depart. Endocrinology and Metab. Diseases
-
Plovdiv, Bulgarien, 4002
- Diagnostic-Consultative Centre "Sveti Georgi" Eood
-
Plovdiv, Bulgarien, 4001
- UMHAT Kaspela EOOD, Endocrinology and Metabolic Diseases Clinic
-
Sofia, Bulgarien, 1431
- USHATE "Akad. Ivan Penchev" Second Clinic of Endocrinology
-
Sofia, Bulgarien, 1431
- UMHAT "Aleksandrovska"
-
Sofia, Bulgarien, 1000
- Medical centre Regina Life Clinic EOOD
-
Sofia, Bulgarien, 1431
- USHATE Akad. Ivan Penchev EAD, Second Clinic of Endocrinology
-
Sofia, Bulgarien, 1431
- UMHAT Aleksandrovska EAD, Densitometry and Bone Metabolic Diseases
-
Varna, Bulgarien, 9020
- AIPSMC Dr. Artin Magardichyan EOOD
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35294
- Uni of Alabama at Birmingham
-
-
California
-
Los Angeles, California, Forenede Stater, 90057
- Velocity Clin Research LA
-
Santa Ana, California, Forenede Stater, 92701
- Southern Cal Clinical Research
-
-
Connecticut
-
Waterbury, Connecticut, Forenede Stater, 06708
- Chase Medical Research LLC
-
-
Florida
-
Fleming Island, Florida, Forenede Stater, 32003
- Fleming Island Ctr for Clin Res
-
Hollywood, Florida, Forenede Stater, 33024
- Encore Medical Research LLC
-
Miramar, Florida, Forenede Stater, 33027
- South Broward Research LLC
-
Orlando, Florida, Forenede Stater, 32825
- Florida Inst For Clin Res
-
Orlando, Florida, Forenede Stater, 32825
- Florida Institute for Clinical research
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60607
- Cedar-Crosse Research Center
-
-
Kansas
-
Topeka, Kansas, Forenede Stater, 66606
- Cotton O'Neil Clinical Research Center
-
-
Kentucky
-
Paducah, Kentucky, Forenede Stater, 42001
- Advanced Internal Medicine, PLLC
-
-
Maryland
-
Hyattsville, Maryland, Forenede Stater, 20782
- Medstar Research Institute_Hyattsville
-
Oxon Hill, Maryland, Forenede Stater, 20745
- MD Medical Research
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02115
- Brigham & Women's Hospital
-
Methuen, Massachusetts, Forenede Stater, 01844
- ActivMed Practice & Research LLC
-
-
Michigan
-
Troy, Michigan, Forenede Stater, 48098
- Arcturus Healthcare, PLC
-
Troy, Michigan, Forenede Stater, 48098
- Arcturus HC PLC Troy Med Res
-
-
Missouri
-
Chesterfield, Missouri, Forenede Stater, 63005
- Clinical Research Professionals
-
City of Saint Peters, Missouri, Forenede Stater, 63303
- StudyMetrix Research LLC
-
-
New York
-
Albany, New York, Forenede Stater, 12203
- AMC Community Endocrinology
-
-
North Carolina
-
Morehead City, North Carolina, Forenede Stater, 28557
- Centricity Rsrch MHCity Multi
-
Statesville, North Carolina, Forenede Stater, 28625
- Piedmont Healthcare/Research
-
-
North Dakota
-
Fargo, North Dakota, Forenede Stater, 58104
- Lillestol Research LLC
-
Fargo, North Dakota, Forenede Stater, 58104
- Plains Clinical Research Center, LLC_Fargo
-
-
Oklahoma
-
Norman, Oklahoma, Forenede Stater, 73069
- Alliance for Multispec Res
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19107-6810
- Jefferson Endocrinology Assocs
-
Pittsburgh, Pennsylvania, Forenede Stater, 15236
- Preferred Primary Care Physicians_Pittsburgh
-
-
South Dakota
-
Rapid City, South Dakota, Forenede Stater, 57702
- Health Concepts
-
-
Tennessee
-
Kingsport, Tennessee, Forenede Stater, 37660
- Holston Medical Group
-
Nashville, Tennessee, Forenede Stater, 37203
- Clinical Research Associates
-
Nashville, Tennessee, Forenede Stater, 37203
- MidState Endocrine Associates
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75230
- Velocity Clinical Res-Dallas
-
Houston, Texas, Forenede Stater, 77024
- Victorium Clinical Research
-
Houston, Texas, Forenede Stater, 77079
- PlanIt Research, PLLC
-
Houston, Texas, Forenede Stater, 77061
- Synergy Groups Medical
-
Lampasas, Texas, Forenede Stater, 76550
- Radiance Clinical Research
-
McKinney, Texas, Forenede Stater, 75069
- Tekton Research
-
Waco, Texas, Forenede Stater, 76708
- Hillcrest Family Health Center
-
-
-
-
-
Athens, Grækenland, 115 25
- Iatriko Psychicou Private Clinic
-
Athens, Grækenland, 12462
- U.G.H of Athens "Attikon"
-
Goudi/Athens, Grækenland, 11527
- "Laiko" General Hospital of Athens
-
Thessaloniki, Grækenland, GR-54643
- EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
-
Thessaloniki, Grækenland, GR-57001
- "Thermi" Private Hosital
-
Thessaloniki, Grækenland, 564 29
- 424 Military General Training Hospital
-
Thessaloniki, Grækenland, 57001
- "Thermi" Private Hosital
-
Thessaloniki, Grækenland, 54645
- EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
-
Thessaloniki, Grækenland, 564 29
- 424 Military General Training Hospital - 2nd Department of Internal Medicine
-
-
-
-
-
Aichi, Japan, 468-0009
- TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology
-
Chiba, Japan, 261-0004
- Tokuyama clinic_Diabetic internal medicine
-
Chiba, Japan, 261-0004
- Tokuyama clinic
-
Chiba-shi, Chiba, Japan, 260-0804
- Akaicho Clinic
-
Ibaraki, Japan, 311-0113
- Naka Kinen Clinic
-
Ibaraki, Japan, 311-0113
- Naka Kinen Clinic_Internal medicine
-
Tokyo, Japan, 103-0027
- Tokyo-Eki Center-building Clinic
-
Tokyo, Japan, 104-0031
- Fukuwa Clinic
-
Tokyo, Japan, 103-0027
- Tokyo-Eki Center-building Clinic_Internal Medicine
-
Tokyo, Japan, 104-0031
- Fukuwa Clinic_Internal Medicine
-
-
Miyazaki
-
Miyazaki, Miyazaki, Japan, 880-0034
- Heiwadai Hospital_Internal Medicine
-
Miyazaki, Miyazaki, Japan, 880-0034
- Heiwadai Hospital
-
-
-
-
-
Karlovac, Kroatien, 47000
- Opca bolnica Karlovac
-
Krapinske Toplice, Kroatien, 49217
- Specijalna bolnica Krapinske Toplice - Endokrinologija
-
Krapinske Toplice, Kroatien, 49217
- Specijalna Bolnica za medicinsku rehabilitaciju Krapinske Toplice_Endocrinology
-
Osijek, Kroatien, 31 000
- Klinicki bolnicki centar Osijek_Endocrinology
-
Osijek, Kroatien, 31 000
- Klinicki bolnicki centar Osijek
-
Varaždin, Kroatien, 42 000
- Opca bolnica Varazdin_Endocrinology
-
Varaždin, Kroatien, 42 000
- Opca bolnica Varazdin
-
-
City of Zagreb
-
Zagreb, City of Zagreb, Kroatien, 10000
- Poliklinika Solmed
-
-
Primorje-Gorski Kotar County
-
Rijeka, Primorje-Gorski Kotar County, Kroatien, 51 000
- KBC Rijeka, Endokrinologija
-
Rijeka, Primorje-Gorski Kotar County, Kroatien, 51 000
- Clinical Hospital Centre Rijeka_Endocrinology
-
-
-
-
-
Bialystok, Polen, 15-375
- Specderm Poznańska Spółka Jawna
-
Lublin, Polen, 20-718
- EKAMED sp. z o.o.
-
Ruda Śląska, Polen, 41-709
- Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.
-
Warsaw, Polen, 02-507
- PANSTWOWY INSTYTUT MEDYCZNY MSWiA
-
-
Gornoslaskie
-
Ruda Śląska, Gornoslaskie, Polen, 41-709
- Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polen, 31-261
- Med. Cent. Diabet. Endo. Metabol. DIAB-ENDO-MET
-
Oświęcim, Lesser Poland Voivodeship, Polen, 32-600
- Formed 2 Sp. z o.o.
-
-
Lower Silesian Voivodeship
-
Legnica, Lower Silesian Voivodeship, Polen, 59-220
- Beata Mikłaszewicz & Dariusz Dąbrowski "CARDIAMED" s.j.
-
Legnica, Lower Silesian Voivodeship, Polen, 59-220
- Beata Miklaszewicz & Dariusz Dabrowski "CARDIAMED" s.j.
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Polen, 20-718
- EKAMED sp. z o.o.
-
-
Masovian Voivodeship
-
Siedlce, Masovian Voivodeship, Polen, 08-110
- ETG Siedlce
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, Polen, 15-879
- NZOZ Vita-Diabetica Malgorzata Buraczyk
-
Bialystok, Podlaskie Voivodeship, Polen, 15-375
- Specderm Poznanska Sp. j.
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, Polen, 90-302
- Santa Sp. z o.o, Santa Familia Centrum Badan, Profilaktyki i Leczenia
-
-
-
-
-
Brasov, Rumænien, 500101
- Mariodiab Clinic SRL
-
Timișoara, Rumænien, 300723
- Spitalul Clinic Judetean De Urgenta Pius Brinzeu Timisoara
-
Timișoara, Rumænien, 300288
- Cabinet Medical Dr Geru SRL
-
-
Bihor County
-
Oradea, Bihor County, Rumænien, 410025
- SC Grand Med SRL
-
Oradea, Bihor County, Rumænien, 410159
- Grandmed SRL
-
-
Bucharest
-
Bucharest, Bucharest, Rumænien, 020475
- Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
-
-
Bucurestii
-
Bucharest, Bucurestii, Rumænien, 020475
- Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
-
-
Cluj
-
Cluj-Napoca, Cluj, Rumænien, 400006
- Spitalul Clinic Judetean Urgenta Cluj-Napoca
-
-
Mureș County
-
Târgu Mureş, Mureș County, Rumænien, 540142
- Sc Mediab Srl
-
-
Prahova
-
Ploieşti, Prahova, Rumænien, 100018
- Novus Medical Clinica SRL
-
-
-
-
-
Poprad, Slovakiet, 05801
- DENTAVIA s.r.o.
-
Prešov, Slovakiet, 080 01
- DIABETOL, s.r.o.
-
Rimavská Sobota, Slovakiet, 979 01
- OLIVER - MED s.r.o.
-
Žilina, Slovakiet, 010 01
- MEDIVASA, s.r.o., Diabetologicka ambulancia
-
-
Slovak Republic
-
Šahy, Slovak Republic, Slovakiet, 93601
- Peter Farkas MD, s.r.o.
-
-
-
-
-
A Coruña, Spanien, 15006
- Complejo Hospitalario Universitario A Coruña
-
Barcelona, Spanien, 08036
- Hospital Clinic i Provincial
-
Castilleja de la Cuesta, Spanien, 41950
- Hospital Vithas Sevilla
-
Madrid, Spanien, 28007
- Hospital Gregorio Marañón
-
Pontevedra, Spanien
- Complejo Hospitalario de Pontevedra - Hospital de Montecelo
-
Santander, Spanien, 39008
- Hospital Universitario Marqués de Valdecilla
-
Seville, Spanien, 41003
- Clínica Nuevas Tecnologías en Diabetes y Endocrinología
-
Seville, Spanien, 41010
- Hospital Infanta Luisa
-
Seville, Spanien, 41950
- Hospital Nisa Sevilla Aljarafe
-
Seville, Spanien, 41010
- H. Infanta Luisa_Endocrino y Obesidad
-
-
-
-
-
Elsterwerda, Tyskland, 04910
- Zentrum für klinische Studien Südbrandenburg GmbH
-
Elsterwerda, Tyskland, 04910
- Zentrum fuer klinische Studien Suedbrandenburg GmbH
-
Essen, Tyskland, 45136
- InnoDiab Forschung GmbH
-
Hamburg, Tyskland, 22607
- Wendisch/Dahl Hamburg
-
Hamburg, Tyskland, 22607
- Wendisch - Dahl Hamburg - DZHW
-
Münster, Tyskland, 48145
- Institut für Diabetesforschung GmbH Münster - Dr. med. Rose
-
Oldenburg in Holstein, Tyskland, 23758
- RED-Institut für medizinische Forschung und Fortbildung GmbH
-
-
-
-
-
Budapest, Ungarn, 1106
- Bajcsy-Zsilinszky Kórház
-
Budapest, Ungarn, 1134
- MH Egészségügyi Központ
-
Debrecen, Ungarn, 4031
- Debreceni Egyetem
-
Debrecen, Ungarn, H-4031
- Debreceni Egyetem
-
Debrecen, Ungarn, H-4032
- Debreceni Egyetem
-
Gyula, Ungarn, 5700
- Békés Megyei Központi Kórház
-
Kaposvár, Ungarn, 7400
- Somogy Vármegyei Kaposi Mór Oktató Kórház
-
Kaposvár, Ungarn, H-7400
- Somogy Vármegyei Kaposi Mór Oktató Kórház
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, Ungarn, 4032
- Debreceni Egyetem
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male or female, aged 18-75 years (both inclusive) at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus greater or equal to 180 days before screening.
- Stable daily dose(s) greater or equal to 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without SGLT2 inhibitor.
- HbA1c of 7.0-10.0 procent (53-86 mmol/mol) (both inclusive) as assessed by central laboratory at screening.
- Body mass index between greater or equal to 23.0 and below 50.0 kg/m^2.
- Able and willing to adhere to the protocol including wearing a continuous glucose monitoring (CGM) device provided for the study, as judged by the investigator.
Exclusion Criteria:
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: Placebo subcutaneous
Placebo for subcutaneous treatment |
NNC0487-0111 placebo administered subcutanously (under the skin) |
|
Eksperimentel: NNC0487-0111 subcutaneous dose 1
NNC0487-0111 subcutaneous dose 1 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Eksperimentel: NNC0487-0111 subcutaneous dose 2
NNC0487-0111 subcutaneous dose 2 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Eksperimentel: NNC0487-0111 subcutaneous dose 3
NNC0487-0111 subcutaneous dose 3 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Eksperimentel: NNC0487-0111 subcutaneous dose 4
NNC0487-0111 subcutaneous dose 4 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Eksperimentel: NNC0487-0111 subcutaneous dose 5
NNC0487-0111 subcutaneous dose 5 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Eksperimentel: NNC0487-0111 subcutaneous dose 6
NNC0487-0111 subcutaneous dose 6 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Placebo komparator: Placebo oral
Placebo for oral treatment |
NNC0487-0111 placebo administered orally (in the mouth) |
|
Eksperimentel: NNC0487-0111 oral dose 1
NNC0487-0111 oral dose 1 treatment |
NNC0487-0111 administered orally (in the mouth) |
|
Eksperimentel: NNC0487-0111 oral dose 2
NNC0487-0111 oral dose 2 treatment |
NNC0487-0111 administered orally (in the mouth) |
|
Eksperimentel: NNC0487-0111 oral dose 3
NNC0487-0111 oral dose 3 treatment |
NNC0487-0111 administered orally (in the mouth) |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in HbA1c
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
percent point |
From baseline (week 0) to end of treatment (week 36)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Relative change in body weight
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
percent |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body weight
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
kg |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in fasting plasma glucose (FPG)
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
mmol/L |
From baseline (week 0) to end of treatment (week 36)
|
|
CGM: Change in time in range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL)
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
percent points |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body mass index (BMI)
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
kg/m^2 |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in waist circumference
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
cm |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in systolic blood pressure (SBP)
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
mmHg |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in average 24-hour systolic blood pressure (SBP)
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
mmHg |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high sensitivity C-Reactive Protein (hsCRP)
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in total cholesterol
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high-density lipoprotein (HDL) cholesterol
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in low-density lipoprotein (LDL) cholesterol
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in triglycerides
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Number of adverse events
Tidsramme: From baseline (week 0) to end of study (week 40)
|
Count of events |
From baseline (week 0) to end of study (week 40)
|
|
Change in Urinary Albumin/Creatinine Ratio (UACR)
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Participant without macroalbuminuria (UACR < 300 mg/g) at baseline (week 0) developing (yes/no) new onset of macroalbuminuria (UACR ≥ 300 mg/g)
Tidsramme: At end of treatment (week 36)
|
Count of participant |
At end of treatment (week 36)
|
|
Change in eGFR creatinine- and cystatin C based CKD-EPI
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
mL/min/1.73 m^2 |
From baseline (week 0) to end of treatment (week 36)
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Publikationer og nyttige links
Generelle publikationer
- Mora P, Aroda VR, Asong M, Bluher M, Heftdal LD, Carlander AF, Vilsen LN, Rosenstock J. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026 Jul 30:S0140-6736(26)01248-1. doi: 10.1016/S0140-6736(26)01248-1. Online ahead of print.
- Mora P, Aroda VR, Asong M, Bluher M, Carlander AF, Kaltoft M, Vilsen LN, Rosenstock J. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026 Jul 30:S0140-6736(26)01247-X. doi: 10.1016/S0140-6736(26)01247-X. Online ahead of print.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- NN9490-7678
- U1111-1296-9708 (Anden identifikator: World Health Organization (WHO))
- 2023-509412-28 (Anden identifikator: European Medical Agency (EMA))
- 2023 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .